HC Wainwright Has Negative Outlook for LifeMD Q3 Earnings

Key Points

• HC Wainwright has adjusted its Q3 2025 earnings per share estimate for LifeMD from $0.05 to ($0.06), reflecting a negative outlook for the company.
• The consensus for LifeMD's full-year earnings is projected at ($0.56) per share, with estimates for Q4 2025 at ($0.05) and FY2025 at ($0.16).
• Despite the negative forecasts, LifeMD maintains a Buy rating from HC Wainwright, with a price target set at $13.00.

LifeMD, Inc. (NASDAQ:LFMD - Free Report) - Research analysts at HC Wainwright reduced their Q3 2025 EPS estimates for shares of LifeMD in a report issued on Thursday, August 7th. HC Wainwright analyst Y. Chen now forecasts that the company will earn ($0.06) per share for the quarter, down from their prior estimate of $0.05. HC Wainwright has a "Buy" rating and a $13.00 price target on the stock. The consensus estimate for LifeMD's current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for LifeMD's Q4 2025 earnings at ($0.05) EPS and FY2025 earnings at ($0.16) EPS.

A number of other research analysts have also issued reports on the company. BTIG Research lifted their target price on LifeMD from $15.00 to $18.00 and gave the stock a "buy" rating in a report on Wednesday, June 18th. Lake Street Capital decreased their price objective on LifeMD from $18.00 to $14.00 and set a "buy" rating for the company in a research report on Wednesday, August 6th. Wall Street Zen lowered LifeMD from a "buy" rating to a "hold" rating in a research report on Saturday, August 2nd. Finally, KeyCorp decreased their price objective on LifeMD from $14.00 to $12.00 and set an "overweight" rating for the company in a research report on Wednesday, August 6th. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, LifeMD presently has an average rating of "Moderate Buy" and a consensus price target of $12.86.

LifeMD Stock Performance

LFMD stock traded up $0.11 during mid-day trading on Monday, reaching $6.83. The company had a trading volume of 2,621,004 shares, compared to its average volume of 1,671,861. The company has a quick ratio of 0.72, a current ratio of 0.77 and a debt-to-equity ratio of 9.21. The stock has a market capitalization of $323.88 million, a P/E ratio of -32.52 and a beta of 1.72. LifeMD has a one year low of $3.99 and a one year high of $15.84. The stock's 50-day simple moving average is $11.74 and its two-hundred day simple moving average is $8.53.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in LFMD. CWM LLC increased its position in shares of LifeMD by 17.5% during the first quarter. CWM LLC now owns 9,050 shares of the company's stock valued at $49,000 after purchasing an additional 1,351 shares during the period. Nisa Investment Advisors LLC increased its holdings in LifeMD by 148.5% in the second quarter. Nisa Investment Advisors LLC now owns 3,656 shares of the company's stock valued at $50,000 after purchasing an additional 2,185 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in LifeMD by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,647 shares of the company's stock valued at $270,000 after purchasing an additional 2,235 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of LifeMD by 26.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,012 shares of the company's stock worth $70,000 after acquiring an additional 2,895 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of LifeMD by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 822,217 shares of the company's stock worth $4,071,000 after acquiring an additional 2,984 shares in the last quarter. 35.52% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, CFO Marc David Benathen sold 75,000 shares of the firm's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $13.09, for a total value of $981,750.00. Following the transaction, the chief financial officer directly owned 389,554 shares of the company's stock, valued at approximately $5,099,261.86. This trade represents a 16.14% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Justin Schreiber sold 25,000 shares of the firm's stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $13.38, for a total value of $334,500.00. Following the completion of the transaction, the chief executive officer directly owned 2,500,721 shares in the company, valued at $33,459,646.98. The trade was a 0.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 275,000 shares of company stock valued at $3,564,550 over the last 90 days. 18.40% of the stock is currently owned by insiders.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.